X

Trial Profile

Trial of HT-100 in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD)

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Halofuginone (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

24 Mar 2017 Trial focus and secondary endpoints assumed based on purpose of trial.
24 Mar 2017 New trial record
22 Mar 2017 According to an Akashi Therapeutics media release, company has recieved FDA clearance for clinical development of HT-100 in patients with any of the genetic mutations that cause DMD.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com